2023 Fiscal Year Final Research Report
a new treatment for morbid obesity by using gut microbiome after metabolic surgery
| Project/Area Number |
21K08595
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 55010:General surgery and pediatric surgery-related
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
徳永 卓哉 徳島大学, 病院, 助教 (30448328)
西 正暁 徳島大学, 病院, 助教 (70464344)
高須 千絵 徳島大学, 大学院医歯薬学研究部(医学域), 講師 (70582823)
吉川 幸造 徳島大学, 大学院医歯薬学研究部(医学域), 特任教授 (80448331)
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | Metabolic surgery / DJB / 2型糖尿病 / NASH / 腸内細菌叢 / 肝発癌抑制 |
|---|
| Outline of Final Research Achievements |
In this study, we attempted to verify whether obesity, diabetes, and non-alcoholic steatohepatitis could be improved by using the intestinal microbiota after bariatric surgery, as well as the prevention of liver carcinogenesis. Obese diabetic rats were divided into a bariatric surgery group and a laparotomy-only group, and were given postoperative hepatocarcinogenic inducers, and specimens were collected 6 weeks after surgery. As a result, there was no difference in blood sugar between the two groups, but body weight decreased in the bariatric surgery group. Regarding liver tumor formation, no macroscopic tumor formation was observed in either group, but liver precancerous markers were lower in the bariatric surgery group. There were no differences in genetic changes involved in hepatocarcinogenesis, and there were no significant changes in the intestinal flora between the two groups. Therefore, although it was suggested that bariatric surgery may have an inhibitory effect on liver
|
| Free Research Field |
消化器外科学、肥満外科学、腸内細菌学
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究ではMetabolic surgeryによる腸内細菌叢・胆汁酸組成の変化、腸管炎症抑制、透過性低下に着目しインスリン抵抗性・NASH改善、肝発癌抑制効果を検討した。これまで不明とされていたMetabolic surgeryの肝発癌抑制効果を詳細に検討した報告は他に類を見ず、極めて斬新で、今後の肥満や肥満関連疾患に対する治療の一助となり得る。これが判明した際には内科的治療では改善できなかった肥満・2型糖尿病・NASHやそれらに関連する疾患、発癌に対する治療アプローチが一変する可能性があり、またこれまで肥満外科治療適応外とされてきた症例に対しても新たな治療オプションが提示できるかもしれない。
|
